文献速递肾移植

抗心磷脂抗体与肾移植受者12个月移植物功能:预后队列调查

Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该回顾性队列研究纳入446例肾移植受者,检测247例抗心磷脂抗体(ACL),其中101例阳性(41%)。ACL阳性组12个月eGFR显著低于阴性组,且ACL阳性是eGFR下降的独立危险因素,但两组36个月移植物和患者生存及血栓事件无差异。

要点

  • ACL阳性是肾移植后1年内eGFR下降的独立危险因素。
  • ACL阳性组12个月筛查活检肾小管萎缩更严重。
  • ACL阳性未增加36个月血栓事件或移植物丢失风险。

核心结论

  • 无抗磷脂综合征(APS)的ACL阳性是肾移植后第一年eGFR下降的独立危险因素,且不增加血栓事件发生率。

研究设计与样本

  • 观察性、单中心、回顾性队列研究,纳入446例肾移植受者,标准化随访包括36个月移植物和患者生存、12个月eGFR及3个月和12个月筛查活检。

主要发现

  • 247例患者检测ACL,101例阳性(ACL+组,41%),146例阴性(ACL-组,59%)。
  • 36个月移植物和患者生存及血栓事件两组相似(HR分别为1.18和0.98)。
  • 12个月eGFR在ACL+组显著更低[中位数(95%CI)48.5(35.1-60.3)vs 51.9(39.1-65.0)mL/min/1.73 m2,P=0.042]。
  • ACL+与eGFR下降独立相关(P=0.04)。
  • 12个月筛查活检中,ACL+组肾小管萎缩显著更严重(P=0.02)。

临床怎么用

  • 肾移植前ACL检测可能有助于识别术后1年肾功能下降风险较高的患者。
  • 未来可探讨包括mTOR抑制剂在内的特定免疫抑制治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In kidney transplant recipients, anticardiolipin (ACL) antibodies without antiphospholipid syndrome (APS) are found in up to 38% of patients and could be associated with thrombotic events (TEs). However, the prognostic role of ACL regarding kidney transplant and patients outcomes have still not been well defined. METHODS: We conducted an observational, monocentric, retrospective cohort study including 446 kidney transplant recipients and standardized follow-up: 36-month allograft and patient survival, 12-month estimated glomerular filtration rate (eGFR) and 3- and 12-month screening biopsies. RESULTS: ACL tests were run on 247 patients, 101 were positive (ACL+ group, 41%) and 146 were negative (ACL- group, 59%). Allografts and patient survival within 36 months as TE were similar between both groups [hazard ratio (HR) = 1.18 and HR = 0.98, respectively]. The 12-month eGFR was significantly lower in the ACL+ group [median (95% confidence interval) 48.5 (35.1-60.3) versus 51.9 (39.1-65.0) mL/min/1.73 m2, P= 0.042]. ACL+ was independently associated with eGFR decrease (P = 0.04). In 12-month screening biopsies, tubular atrophy was significantly more severe in the ACL+ group compared with the ACL- group (P = 0.02). CONCLUSIONS: ACL without APS before kidney transplantation is an independent risk factor of eGFR decline within the first year post-transplant without over-incidence of TEs. Specific immunosuppressive therapy including mammalian target of rapamycin inhibitors should be discussed in the future.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Gauthier M, Canoui-Poitrine F, Guéry E, et al. Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey. Nephrol Dial Transplant. 2018. PMID: 29346631. doi:10.1093/ndt/gfx353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。